STOCK TITAN
  1. Home
  2. News
  3. EW

Edwards Lifesciences Corp - EW STOCK NEWS

Welcome to our dedicated news page for Edwards Lifesciences (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Edwards Lifesciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Edwards Lifesciences's position in the market.

News
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
Rhea-AI Summary
Edwards Lifesciences Corporation (NYSE: EW) is projecting 2024 global sales of $6.3 - $6.6 billion with a constant currency growth of 8% - 10%. The company expects to commercialize EVOQUE tricuspid valve in Europe and is anticipating U.S. approval mid-2024. Edwards is also reaffirming its 2023 financial guidance and projecting 2024 adjusted earnings per share of $2.70 - $2.80.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
News
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
Rhea-AI Summary
Edwards Lifesciences announces positive one-year results from CLASP IID trial and registry, confirming benefits of PASCAL system for mitral regurgitation reduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.14%
Tags
none
-
News
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
Rhea-AI Summary
Edwards Lifesciences announces successful results from TRISCEND II trial for EVOQUE tricuspid valve replacement system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.14%
Tags
none
News
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
Rhea-AI Summary
Edwards Lifesciences reports Q3 sales growth of 12% to $1.48 billion, with TAVR sales growing 11% and EPS of $0.63. The company received CE Mark for EVOQUE and approval for PASCAL Precision system. Full-year 2023 financial guidance remains unchanged.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.14%
Tags
earnings
-
News
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
Rhea-AI Summary
Edwards Lifesciences announces new data from the PARTNER 3 trial, showing low rates of mortality and stroke at five years for transcatheter aortic valve replacement (TAVR) patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
none
-
News
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
Rhea-AI Summary
Edwards Lifesciences receives CE Mark for EVOQUE tricuspid valve replacement system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
News
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023
Rhea-AI Summary
Edwards Lifesciences to announce Q3 2023 operating results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences earnings
-
News
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
Rhea-AI Summary
Edwards Lifesciences to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
conferences
-
News
EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
Rhea-AI Summary
Edwards Lifesciences reports strong Q2 sales growth of 11% to $1.53 billion, with all product groups achieving double-digit growth. TAVR sales grew 9% to $992 million. Q2 EPS of $0.50, adjusted EPS of $0.66. New 2023 sales growth guidance of 10-13%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.78%
Tags
earnings
News
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 26, 2023
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) to announce Q2 2023 operating results on July 26, 2023. Conference call at 5:00 p.m. ET. Dial (877) 704-2848 or (201) 389-0893 to participate. Live and archived on ir.edwards.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences earnings
Stock EW logo
Edwards Lifesciences Corp

NYSE:EW

EW Rankings

#226 Ranked by Market Cap
#3019 Ranked by Stock Gains
N/A Ranked by Dividends

EW Stock Data

54.34B
595.33M
0.89%
84.02%
1.73%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
US
Irvine

About EW

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.